Journey Medical Co. (NASDAQ:DERM) Short Interest Update

Journey Medical Co. (NASDAQ:DERM) saw a significant growth in short interest in April. As of April 15th, there was short interest totalling 235,500 shares, a growth of 59.0% from the March 31st total of 148,100 shares. Approximately 3.5% of the company’s stock are short sold. Based on an average trading volume of 171,700 shares, the short-interest ratio is currently 1.4 days.

Insider Activity

In related news, CEO Claude Maraoui purchased 10,000 shares of Journey Medical stock in a transaction dated Friday, March 22nd. The shares were acquired at an average price of $3.48 per share, with a total value of $34,800.00. Following the completion of the transaction, the chief executive officer now owns 2,163,430 shares of the company’s stock, valued at approximately $7,528,736.40. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, Director Justin Adam Smith purchased 30,000 shares of Journey Medical stock in a transaction dated Friday, March 22nd. The shares were acquired at an average price of $3.47 per share, with a total value of $104,100.00. Following the completion of the transaction, the director now owns 134,717 shares of the company’s stock, valued at approximately $467,467.99. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Claude Maraoui purchased 10,000 shares of Journey Medical stock in a transaction dated Friday, March 22nd. The shares were bought at an average cost of $3.48 per share, for a total transaction of $34,800.00. Following the transaction, the chief executive officer now directly owns 2,163,430 shares of the company’s stock, valued at approximately $7,528,736.40. The disclosure for this purchase can be found here. Insiders acquired 50,000 shares of company stock worth $169,300 over the last ninety days. Corporate insiders own 19.42% of the company’s stock.

Journey Medical Price Performance

Shares of NASDAQ DERM opened at $3.40 on Friday. The company has a current ratio of 1.35, a quick ratio of 1.10 and a debt-to-equity ratio of 0.72. The stock has a 50-day simple moving average of $3.72. Journey Medical has a 52-week low of $1.02 and a 52-week high of $8.11.

Journey Medical (NASDAQ:DERM) last issued its earnings results on Thursday, March 21st. The company reported ($0.12) earnings per share (EPS) for the quarter. Journey Medical had a negative return on equity of 34.08% and a negative net margin of 4.87%. The business had revenue of $15.26 million during the quarter, compared to the consensus estimate of $15.80 million. On average, analysts predict that Journey Medical will post -0.83 EPS for the current year.

Analysts Set New Price Targets

Separately, Alliance Global Partners initiated coverage on shares of Journey Medical in a report on Friday, February 16th. They issued a “buy” rating and a $8.50 target price on the stock.

Journey Medical Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.